US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Small Pharma Inc (OP:DMTTF)

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Small Pharma Inc

< Previous 1 2 Next >
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
News headline image
Small Pharma Reports Fiscal Second Quarter 2024 Highlights
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Obtains Final Order Approving Arrangement
From Cybin Inc.
Via Business Wire
News headline image
Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Cybin to Acquire Small Pharma Inc.
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for... 
Via Newsfile
Topics Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Acquisition That Will Create ‘Clear Market Leader in Novel Psychedelic Therapeutics’
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin to Acquire Small Pharma Inc.
From Cybin Inc.
Via Business Wire
News headline image
Small Pharma Reports Fiscal First Quarter 2024 Highlights
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces SPL028 R&D Strategy Update
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces Management Team Change
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces Significant Developments In Intellectual Property Portfolio
5 new patent grants, 3 expected upcoming patent grants, and 8 notices of allowance in key international jurisdictions 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
Chief Medical and Scientific Officer, Dr. Carol Routledge, will deliver a poster presentation on data from the Company’s SPL026 Phase IIa clinical trial in patients with Major Depressive Disorder 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-months 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference
Company will also host a cocktail reception on Tuesday, March 7 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental 
Via PressReach
News headline image
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
From Small Pharma Inc.
Via GlobeNewswire
News headline image
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
Study will compare the profile of intramuscular versus intravenous SPL026 administration 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
From Small Pharma Inc.
Via GlobeNewswire
News headline image
First Patient Dosed in Small Pharma’s Drug Interaction Study
Open-label study will assess the interaction between SSRI antidepressants and SPL026 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma To Support University College London Research Project on Neuroplasticity
Small Pharma will provide SPL026 for the brain-imaging study, which seeks to explore how psychedelic-induced brain changes impact cognition, behaviour and well-being 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium
From Small Pharma Inc.
Via GlobeNewswire
< Previous 1 2 Next >